Applied Research on a Non-pharmacological Intervention Program for Older Adults With Subjective Cognitive Decline
1 juin 2026 mis à jour par: Zhi Cai, China Medical University, China
Applied Research on a Group-based Non-pharmacological Intervention Program for Community-dwelling Older Adults With Subjective Cognitive Decline
This study aims to verify the short-term and long-term effects of a group-based non-pharmacological intervention program for community-dwelling older adults with subjective cognitive decline, and to evaluate its implementation outcomes, through a rigorously designed cluster randomized controlled trial.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Description détaillée
This study adopts a cluster randomized controlled design to implement a group-based non-pharmacological intervention for older adults with subjective cognitive decline.
The effects of the intervention on global cognitive function, episodic memory, executive function, attention, language function, subjective memory function, anxiety, depression, social participation, gait speed, physical activity level, and healthy lifestyle behaviors will be evaluated.
In addition, implementation outcomes will be assessed based on the RE-AIM framework and the CFIR framework.
Type d'étude
Interventionnel
Inscription (Estimé)
218
Phase
- N'est pas applicable
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria Aged ≥60 Community dwelling Subjective memory decline, confirmed by Subjective Cognitive Decline Questionnaire(SCD-Q9)≥5 Montreal Cognitive Assessment (MoCA) scores ≥19, 22, or 24 for participants who had primary school, middle school, or higher education, respectively Overall intact activities of daily living No planned exercise or cognitive intervention activities within the past six months Voluntary participants who will be informed of the study objectives by the researcher and will sign the informed consent form.
Exclusion Criteria Any other neurodegenerative diseases (such as mild cognitive impairment, dementia, Parkinson's disease, stroke, etc.) Any severe or unstable internal medical conditions (i.e., unstable or severe asthma or heart disease, liver and kidney diseases, uncontrolled hypertension, severe metabolic diseases, etc.) Severe depressive, anxiety or other psychiatric disorders Movement contraindications Those currently participating in other research trials.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Non-Pharmacological Interventions
|
6 components(social intercourse, cognitive interventions, physical activities interventions, rational diet, understanding and risk management of diseases, emotion management)
|
|
Autre: Waiting List Control Group
To ensure ethical fairness, the same intervention program will subsequently be provided to the waitlist control group after positive effects are confirmed in the intervention group.
|
To ensure ethical fairness, the same intervention program will subsequently be provided to the waitlist control group after positive effects are confirmed in the intervention group.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Episodic memory
Délai: week0，week12，week24
|
Using the Huashan version of the Auditory Verbal Learning Test (AVLT) for assessment, it is mainly used to evaluate immediate recall, short-delay recall, long-delay recall, and other key components.
The test includes 12 words belonging to three semantic categories (4 words per category).
The testing procedure is as follows: The examiner reads out the 12 words in sequence, and the subject immediately recalls them.
This process is repeated three consecutive times to form the immediate memory test.
After an interval of 5 minutes, short-delay recall is conducted, and after 20 minutes, long-delay recall is implemented.
The scoring rule is that each correctly recalled word earns 1 point.
The immediate memory score is the sum of correct recalls from the first three trials (maximum score 36).
This study records the scores for immediate recall, short-delay recall, and long-delay recall, with higher scores indicating better memory function.
|
week0，week12，week24
|
|
Gobal cognitive function
Délai: week0，week12，week24
|
The assessment uses the Montreal Cognitive Assessment (MoCA).
Higher scores indicate better performance, with a minimum score of 0 and a maximum score of 30.
|
week0，week12，week24
|
|
Executive function
Délai: week0，week12，week24
|
The Shape Trail Test (STT) was used to assess executive function.
The test consists of two parts: Part A requires participants to connect 25 numbers in ascending order; Part B involves 25 numbers presented within two different shapes.
The scoring indicators are the time taken to complete STT-A and STT-B, with shorter completion times indicating better executive function.
|
week0，week12，week24
|
|
Attention
Délai: week0，week12，week24
|
The Digit Symbol Substitution Test (DSST) is used to assess the patient's attention.
The subject is required to match the corresponding symbols to the numbers (1-9) as quickly as possible within 90 seconds.
Each correctly filled symbol earns 1 point, and a reversed symbol earns 0.5 points.
The maximum score for the test is 90.
|
week0，week12，week24
|
|
Linguistic function
Délai: week0，weel12，week24
|
Animal verbal fluency is used to assess a patient's language fluency.
The test requires the subject to name as many examples as possible within the category of animals in one minute.
Scoring is typically based on the total number of correctly named animal names.
Lower scores indicate reduced language ability.
|
week0，weel12，week24
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Depression
Délai: week0，weel12，week24
|
The short version of the Geriatric Depression Scale (Geriatric Depression Scale-15, GDS-15) is used for assessment.
The total score ranges from 0 to 15, and the score is positively correlated with the severity of depression.
|
week0，weel12，week24
|
|
Anxiety
Délai: week0，week12，week24
|
The Geriatric Anxiety Inventory-20 (GAI-20) is used for assessment.
This scale consists of 20 items, and respondents answer based on their emotional feelings over the past week.
A response of "Yes" is scored as 1 point, while "No" is scored as 0 points.
The total score ranges from 0 to 20, with higher scores indicating more severe anxiety.
|
week0，week12，week24
|
|
Social network
Délai: week0，week12，week24
|
The Lubben Social Network Scale-6 (LSNS-6) is a short version of the Lubben Social Network Scale.
It is primarily used to measure an individual's level of social connectedness in two dimensions: family relationships and peer interactions.
The scale consists of six assessment items and uses a graded scoring system: 0 points indicate no such social members, 1 point corresponds to 1 person, 2 points to 2 people, 3 points to 3-4 people, 4 points to 5-8 people, and 5 points applies to groups of 9 or more individuals.
Lower scores indicate poorer levels of social network connectedness.
|
week0，week12，week24
|
|
Social participation
Délai: week0，week12，week24
|
This study employed the Social Participation Level Assessment Tool revised by Wei Xiuping, which was developed based on national health survey data of the elderly population.
The measurement tool comprises two main dimensions: cultural organization participation and family/personal affairs, encompassing a total of 10 specific items.
A five-point Likert scale was used for measurement, and the total score is positively correlated with the level of social participation-that is, a higher score indicates a more significant degree of social participation among the respondents.
|
week0，week12，week24
|
|
Timed "Up and Go" test
Délai: week0，week12，week24
|
During the test, the participant sits on a chair with armrests and a backrest.
Upon hearing the instruction, they stand up, walk 3 meters forward at their usual gait, then turn around, return to the chair, and sit down.
The average of two test trials is recorded.
|
week0，week12，week24
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
30 juin 2026
Achèvement primaire (Estimé)
30 juin 2029
Achèvement de l'étude (Estimé)
1 décembre 2029
Dates d'inscription aux études
Première soumission
20 mai 2026
Première soumission répondant aux critères de contrôle qualité
1 juin 2026
Première publication (Réel)
5 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
5 juin 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
1 juin 2026
Dernière vérification
1 juin 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 【2026】161
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .